生物制药公司Arbutus Biopharma Corporation近日公开表示，其对于欧洲专利局（EPO）近期作出的专利裁决结果持不同意见。公司方面明确表态不接受该裁决结论，并已着手准备向EPO扩大申诉委员会提交复审请愿。这一法律行动彰显了Arbutus对其知识产权组合的坚定捍卫立场，也反映出生物医药领域专利争议的复杂性与重要性。
生物制药公司Arbutus Biopharma Corporation近日公开表示，其对于欧洲专利局（EPO）近期作出的专利裁决结果持不同意见。公司方面明确表态不接受该裁决结论，并已着手准备向EPO扩大申诉委员会提交复审请愿。这一法律行动彰显了Arbutus对其知识产权组合的坚定捍卫立场，也反映出生物医药领域专利争议的复杂性与重要性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.